The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.
It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Patients aged 19 years and older
Histologically confirmed diagnosis of gastric cancer
Patients followed in the participating oncology departments
Informed consent obtained
None
Patients with histologically confirmed gastric cancer, followed in the participating oncology departments.
Other
Cross-sectional
Not listed
Demographic characteristics of patients with gastric cancer in Algeria
The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²).
Sociological characteristics of patients with gastric cancer in Algeria
The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin)
Epidemiological characteristics of patients with gastric cancer in Algeria.
Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances.
Clinical characteristics of patients with gastric cancer in Algeria.
Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification.
Diagnostic modalities in patients with gastric cancer in Algeria
Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis.
Therapeutic management modalities
Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up.
Click on the lead sponsor to view all of their trials.
Société Algérienne de Formation et Recherche en Oncologie
Lead sponsor
Bristol-Myers Squibb
Collaborator
ES Clinical Research
Collaborator